Combination therapy with an angiotensin-converting-enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy

Journal of Diabetes Investigation

Volumn 4, Issue 2, 2013, Pages 195-201

  Nakamura, Akihiko ^a,b   Shikata, Kenichi ^c,d   Nakatou, Tatsuaki ^b   Kitamura, Takuya ^b   Kajitani, Nobuo ^b,c   Ogawa, Daisuke ^c,e   Makino, Hirofumi ^c  

^a Department of Internal Medicine   (Japan)

^b OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^c Department of Medicine and Clinical Science ^*  (Japan)

^d OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

Author keywords

Combination; Diabetic nephropathy; Renin angiotensin system

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; C REACTIVE PROTEIN; IMIDAPRIL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG EFFICACY; FEMALE; HUMAN; JAPANESE; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; URINARY EXCRETION;

EID: 84878363986     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12004     Document Type: Article

References (27)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1990; 340: 115-126.
2. Fornoni A, Ijaz A, Tejada T, etal. Role of inflammation in diabetic nephropathy. Curr Diabetes Rev 2008; 4: 10-17.
3. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 433-442.
4. Blake GJ, Rifai N, Buring JE, etal. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993-2999.
5. Abrahamian H, Endler G, Exner M, etal. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. Exp Clin Endocrinol Diabetes 2007; 115: 38-41.
6. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67: 799-812.
7. Ferrari P. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. Nephrology 2007; 12: 81-89.
8. Tomohiro T, Kumai T, Sato T, etal. Hypertension aggravates glomerular dysfunction with oxidative stress in a rat model of diabetic nephropathy. Life Sci 2007; 80: 1364-1372.
9. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, etal. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005; 45: 39-47.
10. Mori T, Cowley AW Jr. Role of pressure in angiotensin II-induced renal injury: chronic servo-control of renal perfusion pressure in rats. Hypertension 2004; 43: 752-759.
11. Tojo A, Onozato ML, Kobayashi N, etal. Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure. Hypertension 2002; 40: 834-839.
12. Ogawa S, Mori T, Nako K, etal. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006; 47: 699-705.
13. Kunz R, Friedrich C, Wolbers M, etal. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48.
14. Jennings DL, Kalus JS, Coleman CI, etal. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007; 24: 486-493.
15. Yusuf S, Teo KK, Pogue J, etal. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
16. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121-128.
17. Yoshii T, Iwai M, Li Z, etal. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res 2006; 29: 457-466.
18. Kataoka C, Egashira K, Ishibashi M, etal. Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. Am J Physiol Heart Circ Physiol 2004; 286: 768-774.
19. Koh KK, Ahn JY, Han SH, etal. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905-910.
20. Chen R, Iwai M, Wu L, etal. Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension 2003; 42: 542-547.
21. Nakamura A, Shikata K, Hiramatsu M, etal. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 2005; 28: 2890-2895.
22. Lapteva N, Ide K, Nieda M, etal. Activation and suppression of renin-angiotensin system in human dendritic cells. Biochem Biophys Res Commun 2002; 296: 194-200.
23. Pan HZ, Chang D, Feng LG, etal. Oxidative damage to DNA and its relationship with diabetic complications. Biomed Environ Sci 2007; 20: 160-163.
24. Xu GW, Yao QH, Weng QF, etal. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients. J Pharm Biomed Anal 2004; 36: 101-104.
25. Arnalich F, Hernanz A, Lopez-Maderuelo D, etal. Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. Horm Metab Res 2000; 32: 407-412.
26. Imai E, Chan JC, Ito S, etal. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011; 54: 2978-2986.
27. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.